Sclerosis (medicine)

NYSE to Commence Delisting Proceedings Against Global Cord Blood Corporation (CO)

Retrieved on: 
Wednesday, June 7, 2023
Professional Services, Finance, NYSE Listed Company Manual, Grand Court Order of Calanthe, Exchange, Bangladesh Securities and Exchange Commission, Committee, Cayman Islands, Security (finance), Sclerosis (medicine), NYSE, Cryptocurrency

The New York Stock Exchange LLC (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the ordinary shares of Global Cord Blood Corporation (the “Company”) — ticker symbol CO — from the NYSE.

Key Points: 
  • The New York Stock Exchange LLC (“NYSE” or “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the ordinary shares of Global Cord Blood Corporation (the “Company”) — ticker symbol CO — from the NYSE.
  • NYSE Regulation halted trading in the Company’s ordinary shares on September 23, 2022 and has now determined to commence delisting proceedings with respect to the Company pursuant to Section 802.01D of the NYSE Listed Company Manual.
  • On September 22, 2022, the Grand Court of the Cayman Islands issued an order appointing Joint Provisional Liquidators (the “JPLs”) over the Company.
  • As a result, NYSE Regulation reached the decision that the Company is no longer suitable for listing.

GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

Retrieved on: 
Thursday, April 13, 2023
Cayman, Failure, Grand Court Order of Calanthe, NYSE Listed Company Manual, Regulation, Order, Companies Act, GEORGE, Form 6-K, Sclerosis (medicine), NYSE, Companies Act 2006, Cryptocurrency, Court

As the JPLs' investigations into the Company's financial position is ongoing,  the Company was unable to complete and file the Interim Financials in a timely manner.

Key Points: 
  • As the JPLs' investigations into the Company's financial position is ongoing,  the Company was unable to complete and file the Interim Financials in a timely manner.
  • The Company cannot at this time estimate the anticipated filing date of the Interim Financials.
  • In accordance with applicable NYSE rules, the Company has until September 30, 2023, to regain compliance with the NYSE listing standards by filing the Interim Financials on Form 6-K (and any subsequent delayed filings).
  • In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

GLOBAL CORD BLOOD CORPORATION ANNOUNCES FAILURE TO FILE INTERIM FINANCIALS

Retrieved on: 
Thursday, April 13, 2023
Cayman, Failure, Grand Court Order of Calanthe, NYSE Listed Company Manual, Regulation, Order, Companies Act, GEORGE, Form 6-K, Sclerosis (medicine), NYSE, Companies Act 2006, Cryptocurrency, Court

As the JPLs' investigations into the Company's financial position is ongoing,  the Company was unable to complete and file the Interim Financials in a timely manner.

Key Points: 
  • As the JPLs' investigations into the Company's financial position is ongoing,  the Company was unable to complete and file the Interim Financials in a timely manner.
  • The Company cannot at this time estimate the anticipated filing date of the Interim Financials.
  • In accordance with applicable NYSE rules, the Company has until September 30, 2023, to regain compliance with the NYSE listing standards by filing the Interim Financials on Form 6-K (and any subsequent delayed filings).
  • In addition, the Company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date hereof.

NRG Therapeutics Appoints Gilles Ouvry Ph.D. as Vice President of Chemistry to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders

Retrieved on: 
Thursday, February 9, 2023
Neurodegeneration, WEHI, Medicine, Mitochondrial permeability transition pore, Degenerative disease, IND, R, Neuroinflammation, MOA, CSO, Survival, Therapy, Drug development, NRG, Drug discovery, Mitochondrion, MND, Sclerosis (medicine), ALS, MPTP, SBC, École Polytechnique, Cell, AstraZeneca, Pharmaceutical industry, Fine chemical, Galderma, Chemistry, Evotec

Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.

Key Points: 
  • Dr Ouvry brings 20 years of international medicinal chemistry experience gained at Evotec, Galderma, AstraZeneca and SCYNEXIS.
  • NRG Therapeutics’ co-founder and CEO Dr Neil Miller said, “We are expanding following our £16m series A financing and I am delighted to welcome Gilles to our team.
  • There is now a substantial body of evidence demonstrating mitochondrial failure or dysfunction is common across many degenerative diseases.
  • Gilles Ouvry Ph.D., VP of Chemistry at NRG Therapeutics said, “I have been impressed by the potential of NRG’s small molecules and am excited to be working with the team to move the programs forward.

FTX Debtors and FTX DM (Bahamas) Announce Cooperation Agreement

Retrieved on: 
Friday, January 6, 2023
FTX, Agreement, Sclerosis (medicine), Supreme Court of the Bahamas, Multimedia, Digital marketing system, Title 11 of the United States Code, Rest, Supreme court, Bankruptcy, Securities commission, United States bankruptcy court, Joint, Securities Commission of New Zealand, Credit

WILMINGTON, Del. and NASSAU, Bahamas, Jan. 6, 2023 /PRNewswire/ -- FTX Trading Ltd. (d.b.a. FTX.com), and its affiliated debtors (together, the "FTX Debtors"), and FTX Digital Markets Ltd. ("FTX DM"), acting by the Joint Provisional Liquidators (Brian Simms, K.C., Peter Greaves and Kevin Cambridge), today announced their agreement on terms for mutual cooperation in the chapter 11 cases of the FTX Debtors in Delaware and the provisional liquidation of FTX DM in The Bahamas. 

Key Points: 
  • FTX.com), and its affiliated debtors (together, the "FTX Debtors"), and FTX Digital Markets Ltd. ("FTX DM"), acting by the Joint Provisional Liquidators (Brian Simms, K.C., Peter Greaves and Kevin Cambridge), today announced their agreement on terms for mutual cooperation in the chapter 11 cases of the FTX Debtors in Delaware and the provisional liquidation of FTX DM in The Bahamas.
  • The parties have agreed on parameters for involving FTX DM in the chapter 11 cases and for involving the FTX Debtors in proceedings in The Bahamas.
  • The agreement is subject to the approval of the U.S. Bankruptcy Court in Delaware and the Supreme Court of The Bahamas.
  • The FTX Debtors will file the Agreement on the docket in the chapter 11 cases shortly, and it will be available at https://cases.ra.kroll.com/FTX/ .

The Grand Court of the Cayman Islands Granted Blue Ocean’s Application to Appoint Joint Provisional Liquidators for Global Cord Blood Corporation

Retrieved on: 
Friday, September 23, 2022
Professional Services, Finance, Companies Act, Cayman, Public Utility Holding Company Act of 1935, Grand Cayman, NYSE, Order, Company, Sclerosis (medicine), Exercise, Security (finance), Holding company, Court, Blue Ocean Strategy

Blue Ocean Structure Investment Company Ltd., (Blue Ocean) a significant shareholder of Global Cord Blood Corporation (the Company or Global Cord) (NYSE: CO), today announced the Grand Court of the Cayman Islands (the Court) issued an order granting the appointment of joint provisional liquidators (JPLs) for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022.

Key Points: 
  • Blue Ocean Structure Investment Company Ltd., (Blue Ocean) a significant shareholder of Global Cord Blood Corporation (the Company or Global Cord) (NYSE: CO), today announced the Grand Court of the Cayman Islands (the Court) issued an order granting the appointment of joint provisional liquidators (JPLs) for Global Cord, pursuant to section 104(2) of the Companies Act (2022 Revision) (the "Companies Act"), upon the application filed by Blue Ocean dated 22 August 2022.
  • Margot MacInnis and John Royle of Grant Thornton Specialist Services (Cayman) Limited, 2nd Floor, Century Yard, Cricket Square, Grand Cayman KY1-1102, Cayman Islands and Chow Tsz Nga Georgia have been appointed as JPLs of the Company.
  • For more details of the Order, please refer to Blue Oceans 13D filing at: https://www.sec.gov/Archives/edgar/data/1729271/000110465922102561/tm222...
    Blue Ocean, as the largest shareholder of Global Cord, has always put the Company and all its shareholders interests as top priority and is determined to safeguard all shareholders investments in Global Cord.
  • Blue Ocean is glad to learn its application for the appointment of the JPLs for Global Cord has been approved by the Court; and believes the Companys assets will be protected and managed in a fair, impartial and unbiased manner.

Global Central Nervous System Partnering Deals Directory 2022: Trends, Players and Financials for 1,700+ Deals Signed Since 2015 - ResearchAndMarkets.com

Retrieved on: 
Thursday, August 18, 2022
Health, Other Health, Parkinson's disease, Restless legs syndrome, Disease, CNS, Directory, Technology, Dizziness, SEC, Finance, Chapter Four, Multiple sclerosis, Chapter Five, Central nervous system, Chapter Three, Haemophilus influenzae, Restless, Guillain–Barré syndrome, Review, Stroke, Contract, Traumatic brain injury, Amyotrophy, Players, Bacteria, Peripheral neuropathy, Weakness, Chapter Six, Cerebral palsy, Chapter One, Chapter Two, Vertigo, Hyperlink, Migraine, Peripheral nervous system, Spinal cord, Creutzfeldt–Jakob disease, Headache, Mycobacterium tuberculosis, Sclerosis (medicine), TB, A-Z, Pharmaceutical industry, Bank, Risk management, Petroleum, Nausea, Stuttering, Fibromyalgia, Meningitis, Epilepsy, Paralysis, Neuralgia, Pain, Haemophilus

The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.

Key Points: 
  • The Global Central Nervous System Partnering 2015-2022 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • Chapter 6 provides a comprehensive directory of all Central Nervous System partnering deals by specific Central Nervous System target announced since 2015.
  • Global Central Nervous System Partnering 2015 to 2022 includes:
    In Global Central Nervous System Partnering 2015 to 2022, available deals and contracts are listed by:

Brisbane Lions Honor Two Passionate Lions Fans Who Are Advancing Potential Solutions for MND Patients

Retrieved on: 
Thursday, February 3, 2022
Research, Mental Health, Medical Devices, Surgery, Clinical Trials, Biotechnology, General Health, Health, Science, Other Science, Docklands Stadium, Brisbane Bears, CEO, Patient, Amyotrophic lateral sclerosis, Epilepsy, Silicon, MD, ALS, BCI, Brisbane Lions, AFL, Technology, Stroke, MND, Nervous system, VFL/AFL, Hypertension, Skull, Doctor of Philosophy, Paralysis, Depression, MNP, Fitzroy Football Club, Neuroprosthetics, Multimedia, History, Sclerosis (medicine), Nightclub, Medical device, Amusement park, Beckman Coulter, Stent-electrode recording array, the StentrodeTM, Synchron, Inc., the Brisbane Lions, THE STENTRODETM, SYNCHRON, INC., THE BRISBANE LIONS

OKeefe was honored, along with Synchron CEO Thomas Oxley, MD, PhD, for their contributions to advancing this technological solution for people with MND.

Key Points: 
  • OKeefe was honored, along with Synchron CEO Thomas Oxley, MD, PhD, for their contributions to advancing this technological solution for people with MND.
  • The MND Victoria organization participated in the event and shared its gratitude to both honorees as well as the entire Brisbane Lions football club.
  • We cannot thank the Lions enough for the wonderful surprise and thrill given to Phil today who is just so passionate about the Lions.
  • The Brisbane Lions were formed on 4 July, 1996, when the AFL approved a merger between the Brisbane Bears and the Fitzroy Lions.

2021 Global Central Nervous System Partnering Directory: Deal Trends, Players and Financials - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 4, 2022
Health, General Health, CNS, Dizziness, Disease, Central nervous system, Players, Peripheral neuropathy, Haemophilus influenzae, Restless, Stroke, Headache, A-Z, Creutzfeldt–Jakob disease, Migraine, Contract, Traumatic brain injury, Mycobacterium tuberculosis, Parkinson's disease, Guillain–Barré syndrome, Research, Hyperlink, Finance, Amyotrophy, Sclerosis (medicine), Multiple sclerosis, Restless legs syndrome, Bacteria, Weakness, Biotechnology, Technology, Cerebral palsy, Collection, Peripheral nervous system, Spinal cord, Vertigo, TB, Cryptocurrency, Pharmaceutical industry, Paralysis, Pain, Meningitis, Epilepsy, Haemophilus, Fibromyalgia, Stuttering, Neuralgia, Nausea

The "Global Central Nervous System Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Central Nervous System Partnering 2014-2021: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
  • Global Central Nervous System Partnering 2014 to 2010 provides the full collection of Central Nervous System disease deals signed between the world's pharmaceutical and biotechnology companies since 2014.
  • The report takes readers through the comprehensive Central Nervous System disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Central Nervous System deals.
  • In Global Central Nervous System Partnering 2014 to 2021, available deals and contracts are listed by:

MAC Assets Corp. Issues Open Letter to Shareholders, CBs, JPLs, and BOD of Luckin Coffee Inc.

Retrieved on: 
Monday, December 13, 2021
Retail, Professional Services, Food, Beverage, Finance, Director, Luckin Coffee, Company, Board, Coffee, Articles of association, CBS, Shareholder, Sclerosis (medicine), Memorandum, MAC, BOD, Shareholder rights plan, Letter, Holding company, Security (finance), Association

MAC Assets Corp., a minority shareholder of Luckin Coffee Inc., recently issued a letter to the Shareholders, Convertible Bondholders, Joint Provisional Liquidators and Board of Directors of Luckin Coffee to call for all minority shareholders to work together and support the Company completely cutting its relationship with the previous management.

Key Points: 
  • MAC Assets Corp., a minority shareholder of Luckin Coffee Inc., recently issued a letter to the Shareholders, Convertible Bondholders, Joint Provisional Liquidators and Board of Directors of Luckin Coffee to call for all minority shareholders to work together and support the Company completely cutting its relationship with the previous management.
  • Below is the full text of the letter:
    Dear Shareholders, CBs, JPLs, and BOD of Luckin Coffee Inc.:
    We, an institutional investor holding Luckin Coffees stocks, has been long paying attention to the development of Luckin Coffee (the Company).
  • Moreover, we have known from the capital market that the previous management has been trying to acquire the Companys shares in covert ways.
  • Currently, the Company has been in a sound development, and is expected to create greater values for shareholders in the future.